(Q33378309)

English

Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

based on heuristic

inferred from title

Christian Geisler

3

object named as

Christian Geisler

0 references

5

object named as

Harald Holte

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

object named as

Eva Kimby

1

1 reference

ORCID Public Data File 2021

4

object named as

Hans Hagberg

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

Jesper Jurlander

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Christian Geisler

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Tuula Lehtinen

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Björn Ostenstad

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Mads Hansen

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Anders Osterborg

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Ola Lindén

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Christer Sundström

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Nordic Lymphoma Group

12

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

1 January 2008

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Leukemia & Lymphoma

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

49

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

102-112

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Treatment strategies in follicular lymphomas: current status and future perspectives

1 reference

https://api.crossref.org/works/10.1080%2F10428190701704647

21 January 2018

From the bench to the bedside: ways to improve rituximab efficacy.

1 reference

https://api.crossref.org/works/10.1080%2F10428190701704647

21 January 2018

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1080%2F10428190701704647

21 January 2018

Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma

1 reference

https://api.crossref.org/works/10.1080%2F10428190701704647

21 January 2018

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

1 reference

https://api.crossref.org/works/10.1080%2F10428190701704647

21 January 2018

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

1 reference

https://api.crossref.org/works/10.1080%2F10428190701704647

21 January 2018

Detection of immunoglobulin gene rearrangement in B lymphoid malignancies by polymerase chain reaction gene amplification

1 reference

https://api.crossref.org/works/10.1080%2F10428190701704647

21 January 2018

Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors.

1 reference

https://api.crossref.org/works/10.1080%2F10428190701704647

21 January 2018

Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule

1 reference

https://api.crossref.org/works/10.1080%2F10428190701704647

21 January 2018

Tolerability and safety of rituximab (MabThera).

1 reference

https://api.crossref.org/works/10.1080%2F10428190701704647

21 January 2018

Rituximab Added to First-Line Mitoxantrone, Chlorambucil, and Prednisolone Chemotherapy Followed by Interferon Maintenance Prolongs Survival in Patients With Advanced Follicular Lymphoma: An East German Study Group Hematology and Oncology Study

1 reference

https://api.crossref.org/works/10.1080%2F10428190701704647

21 January 2018

Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells

1 reference

https://api.crossref.org/works/10.1080%2F10428190701704647

21 January 2018

Identifiers

10.1080/10428190701704647

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33378309&oldid=2067072595"